Cenobamate for focal onset seizures in epilepsy [ID1553]
In development [GID-TA10661] Expected publication date: TBC
Search results
546 results
-
-
Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic [ID2689]
In development [GID-TA10663] Expected publication date: TBC
-
Sarizotan for treating respiratory symptoms in Rett syndrome [ID1506]
In development [GID-TA10662] Expected publication date: TBC
-
Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538
In development [GID-TA10422] Expected publication date: TBC
-
Melanoma (metastatic) - talimogene laherparepvec [ID508]
In development [GID-TAG509] Expected publication date: 28 September 2016
-
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]
In development [GID-TA10168] Expected publication date: TBC
-
Enzalutamide for the treatment of hormone refractory prostate cancer TA316
In development [GID-TA10267] Expected publication date: TBC
-
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]
In development [GID-TA10026] Expected publication date: TBC
-
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]
In development [GID-TA10465] Expected publication date: TBC
-
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]
In development [GID-TA10486] Expected publication date: TBC
-
Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]
In development [GID-TA10484] Expected publication date: TBC
-
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]
In development [GID-TA10491] Expected publication date: TBC
-
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal [TA582] Published date: 24 May 2019
-
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
In development [GID-TA10483] Expected publication date: TBC
-
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466
In development [GID-TA10355] Expected publication date: TBC
-
KTE-X19 for treating relapsed or refractory mantle cell lymphoma [ID1313]
In development [GID-TA10312] Expected publication date: 06 January 2021
-
Spasticity (after stroke) - botulinum toxin type A [ID768]
In development [GID-TAG499] Expected publication date: TBC
-
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
In development [GID-TA10105] Expected publication date: TBC
-
Furosemide micro-pump for treating oedema associated with heart failure (ID1061)
In development [GID-TA10179] Expected publication date: TBC
-
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development [GID-TA10089] Expected publication date: 15 November 2017
-
Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]
In development [GID-TA10616] Expected publication date: TBC
-
Pembrolizumab with fluoropyrimidine and cisplatin for treating recurrent advanced oesophageal cancer [ID3741]
In development [GID-TA10613] Expected publication date: TBC
-
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
In development [GID-TA10617] Expected publication date: TBC
-
Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]
In development [GID-TA10526] Expected publication date: 18 November 2020
-
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
In development [GID-TA10250] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development [GID-TA10623] Expected publication date: TBC
-
Atezolizumab with nab-paclitaxel for neoadjuvant treatment of early triple negative breast cancer [ID1574]
In development [GID-TA10531] Expected publication date: 15 December 2021
-
Avelumab for maintenance treatment of advanced urothelial cancer after platinum-based chemotherapy [ID3735]
In development [GID-TA10624] Expected publication date: TBC
-
Zynteglo for treating transfusion-dependent beta-thalassaemia ID968
In development [GID-TA10334] Expected publication date: TBC
-
Lenvatinib with everolimus or pembrolizumab for untreated advanced renal cell carcinoma [ID3760]
In development [GID-TA10629] Expected publication date: TBC
-
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [ID3761]
In development [GID-TA10630] Expected publication date: TBC
-
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]
In development [GID-TA10632] Expected publication date: TBC
-
Durvalumab for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations and high PD-L1 expression [ID3762]
In development [GID-TA10633] Expected publication date: TBC
-
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia [ID2708]
In development [GID-TA10588] Expected publication date: 24 March 2021
-
Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable ID1564
In development [GID-TA10478] Expected publication date: 10 February 2021
-
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [ID1508]
In development [GID-TA10421] Expected publication date: TBC
-
Recombinant human parathyroid hormone for treating hypoparathyroidism [1094]
Technology appraisal [TA625] Published date: 04 March 2020
-
Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]
In development [GID-TA10222] Expected publication date: 13 January 2021
-
Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509
In development [GID-TA10413] Expected publication date: TBC
-
Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]
In development [GID-TA10567] Expected publication date: 24 November 2021
-
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498
In development [GID-TA10420] Expected publication date: 23 June 2021
-
Selinexor with low-dose dexamethasone for treating refractory multiple myeloma ID1535
In development [GID-TA10412] Expected publication date: 13 January 2021
-
Atezolizumab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic urothelial bladder cancer [ID1206]
In development [GID-TA10202] Expected publication date: 21 July 2021
-
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]
In development [GID-TA10579] Expected publication date: TBC
-
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]
In development [GID-TA10351] Expected publication date: 27 January 2021
-
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [ID1516]
In development [GID-TA10468] Expected publication date: 10 June 2020
-
Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma [ID1625]
In development [GID-TA10643] Expected publication date: TBC
-
Atezolizumab with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer [ID1522]
In development [GID-TA10433] Expected publication date: 24 June 2020
-
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]
In development [GID-TA10470] Expected publication date: TBC
-
Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer [ID1412]
In development [GID-TA10398] Expected publication date: 03 February 2021